Back to School: How biopharma can reboot drug development. Access exclusive analysis here

UCB licenses olokizumab to R-Pharm

UCB Group (Euronext:UCB) granted R-Pharm CJSC (Moscow, Russia) exclusive, worldwide rights to develop and commercialize olokizumab, a

Read the full 171 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE